Trial · NCT00662155
The Role of Partial Reinforcement in the Long Term Management of Insomnia
NCT00662155, Not applicable, Completed, University of Pennsylvania; results first posted 2017-08-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Role of Partial Reinforcement in the Long Term Management of Insomnia. Trials, record NCT00662155. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00662155
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Role of Partial Reinforcement in the Long Term Management of Insomnia
- NCT number
- NCT00662155
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 129 participants, actual
- Lead sponsor
- University of Pennsylvania
- Conditions
- Primary Insomnia
- Interventions
- Zolpidem, Placebos
- First posted
- 2008-04-21
- Last updated
- 2017-08-07
- Results first posted
- 2017-08-07
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Average Sleep Continuity Profile | 12-week average during Phase 3 | The standard measure for clinical trials research in insomnia is the sleep diary. This prospective self-report measurement tool provides an assessment of sleep continuity as a function of treatment. |
| Primary | Overall Average Sleep Efficiency (%) | 12-week average during Phase 3 | The standard measure for clinical trials research in insomnia is the sleep diary. This prospective self-report measurement tool provides an assessment of sleep efficiency (total sleep time/time in bed x 100) as a function of treatment. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Average Sleep Continuity Profile | 12-week average during Phase 3 | These were participants that meant compliance criteria and were included in all analyses. | minutes | MEAN |
| PRIMARY | Overall Average Sleep Efficiency (%) | 12-week average during Phase 3 | These were participants that meant compliance criteria and were included in all analyses. | percent sleep efficiency | MEAN |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Average Sleep Continuity Profile | QHS-10 | Sleep Latency | 28.8 | Standard Error 3.4 | minutes |
| Overall Average Sleep Continuity Profile | IDS-10 | Sleep Latency | 33.8 | Standard Error 4.2 | minutes |
| Overall Average Sleep Continuity Profile | PRS-10 | Sleep Latency | 19.1 | Standard Error 3.8 | minutes |
| Overall Average Sleep Continuity Profile | QHS-5 | Sleep Latency | 20.7 | Standard Error 2.0 | minutes |
| Overall Average Sleep Continuity Profile | QHS-10 | Wake After Sleep Onset | 21.8 | Standard Error 2.6 | minutes |
| Overall Average Sleep Continuity Profile | IDS-10 | Wake After Sleep Onset | 28.4 | Standard Error 5.2 | minutes |
| Overall Average Sleep Continuity Profile | PRS-10 | Wake After Sleep Onset | 20.0 | Standard Error 4.3 | minutes |
| Overall Average Sleep Continuity Profile | QHS-5 | Wake After Sleep Onset | 11.3 | Standard Error 3.6 | minutes |
| Overall Average Sleep Continuity Profile | QHS-10 | Total Sleep Time | 465 | Standard Error 14.4 | minutes |
| Overall Average Sleep Continuity Profile | IDS-10 | Total Sleep Time | 426.1 | Standard Error 9.4 | minutes |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | QHS-10 | 16 | |
| Overall Study | STARTED | IDS-10 | 20 | |
| Overall Study | STARTED | PRS-10 | 20 | |
| Overall Study | STARTED | QHS-5 | 18 | |
| Overall Study | COMPLETED | QHS-10 | 13 | |
| Overall Study | COMPLETED | IDS-10 | 15 | |
| Overall Study | COMPLETED | PRS-10 | 13 | |
| Overall Study | COMPLETED | QHS-5 | 14 | |
| Overall Study | NOT COMPLETED | QHS-10 | 3 | |
| Overall Study | NOT COMPLETED | IDS-10 | 5 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | QHS-10 | ||
| Total, all-cause mortality | IDS-10 | ||
| Total, all-cause mortality | PRS-10 | ||
| Total, all-cause mortality | QHS-5 | ||
| Total, other adverse events | QHS-10 | 0 | 16 |
| Total, other adverse events | IDS-10 | 0 | 20 |
| Total, other adverse events | PRS-10 | 0 | 20 |
| Total, other adverse events | QHS-5 | 0 | 18 |
| Total, serious adverse events | QHS-10 | 0 | 16 |
| Total, serious adverse events | IDS-10 | 0 | 20 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AT003332 | The Role of Partial Reinforcement in the Long Term Management of Insomnia | PERLIS, MICHAEL LLOYD | UNIVERSITY OF PENNSYLVANIA | NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH | 2006 to 2010 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00662155
GET https://conductscience.org/api/trials/v1/NCT00662155/registered